Age (Years) | Median [range] | 53 (24–79) |
<35 (%) | 30 (4Â %) | |
≥70 (%) | 43 (6 %) | |
Type of surgery | Lumpectomy | 552 (73Â %) |
Complete mastectomy | 205 (27Â %) | |
Axillary management | Lymph node dissection | 395 (52Â %) |
Sentinel lymph node biopsy | 362 (48Â %) | |
Histological type | Invasive ductal carcinoma | 599 (79Â %) |
Invasive lobular carcinoma | 66 (9Â %) | |
Other invasive carcinoma | 92 (12Â %) | |
Pathological tumor size (pT) | pT1a-b | 63 (8Â %) |
pT1c | 329 (44Â %) | |
pT2 | 320 (43Â %) | |
pT3-T4 | 36 (5Â %) | |
SBR grade | 1 | 132 (18Â %) |
2 | 331 (44Â %) | |
3 | 285 (38Â %) | |
NA | 9 | |
Peritumoral vascular invasion (PVI) | No | 558 (76Â %) |
Yes | 174 (24Â %) | |
NA | 25 | |
Hormone receptors | ||
 ER | Negative | 229 (31 %) |
Positive | 506 (69Â %) | |
NA | 32 | |
 PR | Negative | 287 (39 %) |
positive | 441 (61Â %) | |
NA | 29 | |
 ER or PR | Negative | 208 (28 %) |
Positive | 527 (72Â %) | |
NA | 22 | |
HER2 status | Positive | 96 (16Â %) |
Negative | 508 (84Â %) | |
NA | 153 | |
IHC subtypes | Triple-negative | 127 (21Â %) |
Luminal A | 290 (49Â %) | |
Luminal B/HER2-negative | 82 (14Â %) | |
Luminal B/HER2-positve | 58 (10Â %) | |
HER2 | 37 (6Â %) | |
NA | 163 | |
Adjuvant chemotherapy | FEC 100 | 716 (94Â %) |
FEC 50/75 | 41 (6Â %) | |
Adjuvant hormone therapy | Yes | 532 (70Â %) |
No | 224 (30Â %) | |
NA | 1 | |
Adjuvant radiation therapy | Yes | 681 (90Â %) |
No | 76 (10Â %) | |
Adjuvant trastuzumab (HER2-positive) | Yes | 40 (41Â %) |
No | 56 (59Â %) |